Video

Dr. Jennifer Miles-Thomas discusses the gender pay gap in urology

Author(s):

Urology Times staff
Conference|LUGPA Annual Meeting
Current Time 0:00
Duration 0:51
Loaded: 19.03%
Stream Type LIVE
Remaining Time 0:51
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    At the 2021 LUGPA Annual Meeting Jennifer Miles-Thomas, MD, FPMRS, president, Urology Of Virginia, participated in a panel discussion titled, “Strategies to Recruit and Retain Female Urologists in your Practice.” In this video, Miles-Thomas discusses the gender pay gap in urology.

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Maria Uloko, MD, on the need for better education on female sexual dysfunction
    Maria Uloko, MD, on the need for better education on female sexual dysfunction
    Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
    Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
    Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
    Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
    Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
    Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
    Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
    Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
    Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
    Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
    Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
    Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
    Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
    Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
    Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
    Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
    Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
    Alternative treatments and patient communication for genitourinary syndrome of menopause
    Related Content
    Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence
    June 25th 2025

    Phase 3 data of oral sulopenem for uUTIs published in NEJM Evidence

    Hannah Clarke
    Oral sulopenem was approved by the FDA in October 2024 for the management of uUTIs.
    Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
    June 2nd 2025

    Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

    Amy M. Pearlman, MD
    Study finds racial/ethnic disparities in use of PSMA-PET in prostate cancer
    June 6th 2025

    Study finds racial/ethnic disparities in use of PSMA-PET in prostate cancer

    Hannah Clarke
    Data showed that Non-Hispanic Black and Latinx/Hispanic patients were less likely to receive PSMA-PET imaging than non-Hispanic White patients.
    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
    May 4th 2025

    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

    Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
    Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
    Jad Chahoud, MD, MPH
    June 5th 2025

    Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

    Benjamin P. Saylor
    ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
    Amy L. Shaver, PhD, PharmD, MPH
    June 5th 2025

    GLP-1 agonist use is rising in men with prostate cancer

    Benjamin P. Saylor
    In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
    © 2025 MJH Life Sciences

    All rights reserved.